PCRX Deadline: PCRX Investors with Losses in Excess of $100K Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Pacira BioSciences, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The Class Period for the Pacira securities is from August 2, 2023, to August 8, 2024, and the lead plaintiff deadline is March 14, 2025 [1]. - Investors can join the class action without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must act by the specified deadline to serve as lead plaintiff [2]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions [3]. - The firm has achieved significant settlements in the past, including the largest securities class action settlement against a Chinese company at the time [3]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [3]. Group 3: Case Background - The lawsuit alleges that statements made by Pacira during the Class Period were misleading, particularly regarding the patent protections on Exparel, which were claimed to be critical for the company's growth [4]. - It is asserted that Pacira was aware of the weaknesses in its patent protections, particularly following a court ruling in favor of eVenus on June 6, 2023, yet continued to publicly affirm the strength of its patent [4]. - The lawsuit claims that when the true nature of the patent protections became known, investors suffered damages [4].